We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. By pressing "Accept All" or closing out of this banner, you accept our Privacy Policy and Terms of Service, revised from time to time, and you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties. You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights Novo Nordisk, AbbVie, AstraZeneca, Air T and United-Guardian
Read MoreHide Full Article
For Immediate Release
Chicago, IL – July 11, 2024 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Novo Nordisk A/S (NVO - Free Report) , AbbVie Inc. (ABBV - Free Report) , AstraZeneca PLC (AZN - Free Report) , Air T, Inc. (AIRT - Free Report) and United-Guardian, Inc. (UG - Free Report) .
Here are highlights from Wednesday’s Analyst Blog:
Top Stocks Reports for Novo Nordisk, AbbVie and AstraZeneca
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Novo Nordisk A/S, AbbVie Inc. and AstraZeneca PLC, as well as two micro-cap stocks, Air T, Inc. and United-Guardian, Inc. These research reports have been hand-picked from roughly 70 reports published by our analyst team today.
Novo Nordisk shares have outperformed the Zacks Large Cap Pharmaceuticals industry over the past year (+84.5% vs. +34.3%). The Zacks analyst believes that the company’s diabetes and obesity drugs segments have been driving business growth, and the company is also gearing up to buy Cardior to help diversify.
Yet, intense rivalry in the obesity sector threatens Novo Nordisk’s market share. Patent expiry and pricing pressure across the diabetes market also remain a major concern.
AbbVie’s shares have underperformed the Zacks Large Cap Pharmaceuticals industry over the past year (+23.9% vs. +34.3%). The Zacks analyst believes that the company faces several near-term headwinds like Humira’s biosimilar erosion, increasing competitive pressure on Imbruvica and decreased demand for fillers in international markets.
Yet, high costs and expenses related to projects and restructuring activities have remained as causes of concern.
Shares of AstraZeneca have underperformed the Zacks Large Cap Pharmaceuticals industry over the past two years (+14.8% vs. +38.9%). Per the Zacks analyst, the company’s diabetes franchise faces stiff competition while the respiratory unit is being hurt by pricing pressure.
Yet, a massive global presence, diverse product portfolio, external acquisitions and strategic collaborations to boost its pipeline are going to aid. Also, key drugs like Lynparza, Tagrisso, Imfinzi, Fasenra, Ultomiris and Farxiga should keep driving revenues.
Air T’s shares have outperformed the Zacks Transportation – Air Freight and Cargo industry over the past six months (+58.4% vs. -6.3%). The Zacks analyst believes that wise acquisitions, higher administrative fees and diversification across four segments have helped drive Air T’s growth in recent months. The WASI acquisition enhances service offerings and geographic reach, contributing to revenue growth. Equity investments and effective cost management bolster financial stability.
However, declining profit margins, high debt levels, negative cash flows, and sector-specific risks and operational losses remain major headwinds.
United-Guardian’s shares have outperformed the Zacks Medical – Products industry over the past year (+15.1% vs. -3.1%). The Zacks analyst believes that discontinuation of low-growth industrial products, focus on higher-margin segments, market strength in cosmetic ingredients and medical lubricants and being supported by a global customer base have helped grow UG’s business.
However, a significant reserve of slow-moving and obsolete inventory, concentration of key customers and supply chain vulnerabilities remain causes for concern.
Since 2000, our top stock-picking strategies have blown away the S&P's +7.0 average gain per year. Amazingly, they soared with average gains of +44.9%, +48.4% and +55.2% per year.
Today you can access their live picks without cost or obligation.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights Novo Nordisk, AbbVie, AstraZeneca, Air T and United-Guardian
For Immediate Release
Chicago, IL – July 11, 2024 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Novo Nordisk A/S (NVO - Free Report) , AbbVie Inc. (ABBV - Free Report) , AstraZeneca PLC (AZN - Free Report) , Air T, Inc. (AIRT - Free Report) and United-Guardian, Inc. (UG - Free Report) .
Here are highlights from Wednesday’s Analyst Blog:
Top Stocks Reports for Novo Nordisk, AbbVie and AstraZeneca
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Novo Nordisk A/S, AbbVie Inc. and AstraZeneca PLC, as well as two micro-cap stocks, Air T, Inc. and United-Guardian, Inc. These research reports have been hand-picked from roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Novo Nordisk shares have outperformed the Zacks Large Cap Pharmaceuticals industry over the past year (+84.5% vs. +34.3%). The Zacks analyst believes that the company’s diabetes and obesity drugs segments have been driving business growth, and the company is also gearing up to buy Cardior to help diversify.
Yet, intense rivalry in the obesity sector threatens Novo Nordisk’s market share. Patent expiry and pricing pressure across the diabetes market also remain a major concern.
(You can read the full research report on Novo Nordisk here >>>)
AbbVie’s shares have underperformed the Zacks Large Cap Pharmaceuticals industry over the past year (+23.9% vs. +34.3%). The Zacks analyst believes that the company faces several near-term headwinds like Humira’s biosimilar erosion, increasing competitive pressure on Imbruvica and decreased demand for fillers in international markets.
Yet, high costs and expenses related to projects and restructuring activities have remained as causes of concern.
(You can read the full research report on AbbVie here >>>)
Shares of AstraZeneca have underperformed the Zacks Large Cap Pharmaceuticals industry over the past two years (+14.8% vs. +38.9%). Per the Zacks analyst, the company’s diabetes franchise faces stiff competition while the respiratory unit is being hurt by pricing pressure.
Yet, a massive global presence, diverse product portfolio, external acquisitions and strategic collaborations to boost its pipeline are going to aid. Also, key drugs like Lynparza, Tagrisso, Imfinzi, Fasenra, Ultomiris and Farxiga should keep driving revenues.
(You can read the full research report on AstraZeneca here >>>)
Air T’s shares have outperformed the Zacks Transportation – Air Freight and Cargo industry over the past six months (+58.4% vs. -6.3%). The Zacks analyst believes that wise acquisitions, higher administrative fees and diversification across four segments have helped drive Air T’s growth in recent months. The WASI acquisition enhances service offerings and geographic reach, contributing to revenue growth. Equity investments and effective cost management bolster financial stability.
However, declining profit margins, high debt levels, negative cash flows, and sector-specific risks and operational losses remain major headwinds.
(You can read the full research report on Air T here >>>)
United-Guardian’s shares have outperformed the Zacks Medical – Products industry over the past year (+15.1% vs. -3.1%). The Zacks analyst believes that discontinuation of low-growth industrial products, focus on higher-margin segments, market strength in cosmetic ingredients and medical lubricants and being supported by a global customer base have helped grow UG’s business.
However, a significant reserve of slow-moving and obsolete inventory, concentration of key customers and supply chain vulnerabilities remain causes for concern.
(You can read the full research report on United-Guardian here >>>)
Why Haven’t You Looked at Zacks' Top Stocks?
Since 2000, our top stock-picking strategies have blown away the S&P's +7.0 average gain per year. Amazingly, they soared with average gains of +44.9%, +48.4% and +55.2% per year.
Today you can access their live picks without cost or obligation.
See Stocks Free >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.